Table II.
Association of p14 ARF genotypes with tumor HPV16 status in SCCOP patients
| p14 ARF genotypes | HPV16-positive patients (n = 439) | HPV16-negative patients (n = 113) | P | Adjusted OR (95% CI)a | ||
|---|---|---|---|---|---|---|
| Number | % | Number | % | |||
| p14 ARF-rs3731217 | ||||||
| TT (Ref.b) | 269 | 61.3 | 88 | 77.9 | 0.001 | 1.0 |
| TG+GG | 170 | 38.7 | 25 | 22.1 | 2.1 (1.3–3.6) | |
| p14 ARF-rs3088440 | ||||||
| GG | 276 | 62.9 | 89 | 78.8 | 0.002 | 1.0 |
| GA+AA | 163 | 37.1 | 24 | 21.2 | 2.4 (1.4–3.9) | |
| Combined variant genotypes | ||||||
| 0 (Ref.b,c) | 196 | 44.6 | 68 | 60.2 | <0.001 | 1.0 |
| 1c | 153 | 34.9 | 41 | 36.3 | 1.3 (0.8–2.1) | |
| 2c | 90 | 20.5 | 4 | 3.5 | 8.0 (2.8–22.3) | |
| Trend | <0.0001 | |||||
P values for χ2 test for genotype distribution.
aAdjusted for age, sex, ethnicity, smoking and alcohol status in a logistic regression model.
bRef. = reference group.
c0: p14 ARF-rs3731217 TT and p14 ARF-rs3088440 GG genotypes; 1: p14 ARF-rs3731217 TT and p14 ARF-rs3088440 GA+AA or p14 ARF-rs3731217 TG+GG and p14 ARF-rs3088440 GG genotypes and 2: p14 ARF-rs3731217 TG+GG and p14 ARF-rs3088440 GA+AA genotypes.